Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.

Area of Science:

• Neuroscience
• Neuropathology
• Proteinopathies

Background:

• Intracytoplasmic alpha-synuclein aggregates (Lewy bodies) in brainstem neurons are diagnostic for Parkinson's disease.
• Cortical Lewy bodies are pathognomonic for dementia with Lewy bodies.
• The relationship between alpha-synuclein pathology, neuronal dysfunction, and clinical symptoms remains unclear.

Purpose of the Study:

• To investigate the origin and progression of alpha-synuclein pathology in the brain.
• To clarify the link between alpha-synuclein aggregation, neuronal dysfunction, and clinical presentation.
• To determine if alpha-synuclein pathology load reliably predicts neurodegenerative disorders.

Main Methods:

• Analysis of 904 autopsy cases with alpha-synuclein pathology in specific brain regions (dorsal motor nucleus of vagus, substantia nigra, basal forebrain).
• Selection based on alpha-synuclein pathology presence, irrespective of clinical phenotype.
• Retrospective clinical assessment of selected cases.

Main Results:

• Only 32% (30/106) of alpha-synuclein-positive cases were clinically diagnosed with a neurodegenerative disorder.
• Alpha-synuclein distribution or load did not reliably predict extrapyramidal symptoms or cognitive impairment.
• Neurologically unimpaired individuals exhibited significant alpha-synuclein pathology in both brainstem and cortical areas.

Conclusions:

• Alpha-synuclein-positive structures are not definitive markers of neuronal dysfunction.
• The presence of Lewy bodies does not invariably indicate clinical neurodegeneration.
• Further research is needed to understand the pathogenic role of alpha-synuclein.